A Selective-Tumor-Penetrating Strategy Via Unidirectional Direct Transfer for Intravesical Therapy of Bladder Cancer

Xiaowen Qin,Heng Wang,Wentao Xu,Bin Zheng,Haibao Zhang,Qi Zhang,Yang Liu,Zhenghong Liu,Li Sun,Yixuan Mou,Cenchao Yao,Wei Zheng,Yiyang Chen,Chenkai Wang,Xuanyi Zhou,Youqing Shen,Pu Zhang,Dahong Zhang

DOI: https://doi.org/10.1021/acs.jmedchem.4c00060

IF: 8.039

2024-01-01

Journal of Medicinal Chemistry

Abstract:A selective tumor-penetrating strategy generally exploits tumor-targeted ligands to modify drugs so that the conjugate preferentially enters tumors and subsequently undergoes transcellular transport to penetrate tumors. However, this process shields ligands from their corresponding targets on the cell surface, possibly inducing an off-target effect during drug penetration at the tumor-normal interface. Herein, we first describe a selective tumor-penetrating drug (R11-phalloidin conjugates) for intravesical therapy of bladder cancer. The intravesical conjugates rapidly translocated across the mucus layer, specifically bound to tumors, and infiltrated throughout the tumor via direct intercellular transfer. Notably, direct transfer from normal cells to tumor cells was unidirectional because the pathways required for direct transfer, termed F-actin-rich tunneling nanotubes, were more unidirectionally extended from normal cells to tumor cells. Moreover, the intravesical conjugates displayed strong anticancer activity and well-tolerated biosafety in murine orthotopic bladder tumor models. Our study demonstrated the potential of a selective tumor-penetrating conjugate for effective intravesical anticancer therapy.